The ASCO Post reports the FDA granted traditional approval to brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma, supported by ZUMA-2 trial findings.
The #FDA has granted a traditional approval to brexucabtagene autoleucel (Tecartus) for the treatment of adult patients with relapsed or refractory mantle cell #lymphoma.
Approval supported by findings from the ZUMA-2 trial.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare